Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers - Concepedia

Concepedia

Publication | Open Access

Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers

DOI Full Paper Access

103

Citations

11

References

2017

Year

Alejandro Arrieta, Jonathan Hong, Rohan Khera, Salim S. Virani, Harlan M. Krumholz, Khurram Nasir

JAMA Cardiology

Abstract

At current prices, the addition of PCSK9i to statin therapy is estimated to provide an additional quality-adjusted life year for $337 729 . Significant discounts are necessary to meet conventional cost-effectiveness standards.

References

	Year	Citations

Page 1